Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 118 articles: HTML format Text format

Single Articles

June 2018
1. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
   Endpoints in diabetes cardiovascular outcome trials.
   Lancet. 2018;391:2412.
   PubMed     Text format    
   
   
   May 2018
2. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
   Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
   Lancet. 2018 May 11. pii: S0140-6736(18)30801.
   PubMed     Text format     Abstract available
   
   
   
3. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
   Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
   Lancet. 2018 May 4. pii: S0140-6736(18)30664.
   PubMed     Text format     Abstract available
   
   
   
4. DAMEN JAAG, Hooft L, Moons KGM
   Contemporary cardiovascular risk prediction.
   Lancet. 2018 May 4. pii: S0140-6736(18)30842.
   PubMed     Text format    
   
   
   April 2018
5. DEHGHAN M, Mente A, Yusuf S
   Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
   Lancet. 2018;391:1681-1682.
   PubMed     Text format    
   
   
   
6. HANSEL B, Roussel R, Giral P
   Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
   Lancet. 2018;391:1680.
   PubMed     Text format    
   
   
   
7. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
   Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
   Lancet. 2018;391:1680-1681.
   PubMed     Text format    
   
   
   
8. CAO XP, Tan CC, Yu JT
   Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
   Lancet. 2018;391:1679-1680.
   PubMed     Text format    
   
   
   
9. CARBONE S, Billingsley H, Abbate A
   Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
   Lancet. 2018;391:1679.
   PubMed     Text format    
   
   
   
10. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    PubMed     Text format    
    
    
    
11. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    PubMed     Text format    
    
    
    
12. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    PubMed     Text format    
    
    
    
13. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    
    
    
    
14. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    
    
    
    
15. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    PubMed     Text format    
    
    
    March 2018
16. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    PubMed     Text format    
    
    
    
17. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    PubMed     Text format    
    
    
    
18. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    PubMed     Text format    
    
    
    
19. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    PubMed     Text format    
    
    
    
20. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    PubMed     Text format     Abstract available
    
    
    February 2018
21. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    PubMed     Text format     Abstract available
    
    
    
22. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    
    
    
    
23. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    
    
    
    January 2018
24. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    PubMed     Text format    
    
    
    
25. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    PubMed     Text format    
    
    
    
26. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    PubMed     Text format    
    
    
    
27. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    PubMed     Text format    
    
    
    
28. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    PubMed     Text format    
    
    
    December 2017
29. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    PubMed     Text format    
    
    
    
30. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    PubMed     Text format    
    
    
    
31. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    PubMed     Text format    
    
    
    
32. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available
    
    
    
33. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    PubMed     Text format     Abstract available
    
    
    November 2017
34. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    PubMed     Text format     Abstract available
    
    
    
35. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    PubMed     Text format     Abstract available
    
    
    
36. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    PubMed     Text format     Abstract available
    
    
    
37. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    PubMed     Text format     Abstract available
    
    
    October 2017
38. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    PubMed     Text format     Abstract available
    
    
    
39. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    PubMed     Text format     Abstract available
    
    
    
40. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    PubMed     Text format    
    
    
    September 2017
41. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    PubMed     Text format     Abstract available
    
    
    August 2017
42. DEHGHAN M, Mente A, Zhang X, Swaminathan S, et al
    Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32252.
    PubMed     Text format     Abstract available
    
    
    
43. MILLER V, Mente A, Dehghan M, Rangarajan S, et al
    Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32253.
    PubMed     Text format     Abstract available
    
    
    
44. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    PubMed     Text format     Abstract available
    
    
    
45. KANDZARI DE, Mauri L, Koolen JJ, Massaro JM, et al
    Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32249.
    PubMed     Text format     Abstract available
    
    
    
46. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    PubMed     Text format     Abstract available
    
    
    
47. CUISSET T, Verheugt FWA, Mauri L
    Update on antithrombotic therapy after percutaneous coronary revascularisation.
    Lancet. 2017;390:810-820.
    PubMed     Text format     Abstract available
    
    
    
48. MINTZ GS, Guagliumi G
    Intravascular imaging in coronary artery disease.
    Lancet. 2017;390:793-809.
    PubMed     Text format     Abstract available
    
    
    
49. THE LANCET
    40 years of percutaneous coronary intervention: where next?
    Lancet. 2017;390:715.
    PubMed     Text format    
    
    
    
50. DAMMAN P, de Winter RJ
    Timing of revascularisation for acute coronary syndrome.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31632.
    PubMed     Text format    
    
    
    
51. JOBS A, Mehta SR, Montalescot G, Vicaut E, et al
    Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31490.
    PubMed     Text format     Abstract available
    
    
    July 2017
52. ALI ZA, Serruys PW, Kimura T, Gao R, et al
    2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Lancet. 2017 Jul 18. pii: S0140-6736(17)31470.
    PubMed     Text format     Abstract available
    
    
    May 2017
53. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    PubMed     Text format     Abstract available
    
    
    April 2017
54. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    PubMed     Text format    
    
    
    
55. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    PubMed     Text format    
    
    
    
56. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    PubMed     Text format    
    
    
    
57. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    PubMed     Text format     Abstract available
    
    
    
58. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    PubMed     Text format    
    
    
    
59. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    PubMed     Text format    
    
    
    
60. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    PubMed     Text format    
    
    
    March 2017
61. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    PubMed     Text format     Abstract available
    
    
    
62. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    PubMed     Text format    
    
    
    
63. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    PubMed     Text format     Abstract available
    
    
    
64. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    PubMed     Text format     Abstract available
    
    
    
65. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    PubMed     Text format    
    
    
    
66. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    PubMed     Text format     Abstract available
    
    
    January 2017
67. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    PubMed     Text format    
    
    
    
68. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    PubMed     Text format    
    
    
    
69. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    PubMed     Text format    
    
    
    
70. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    PubMed     Text format     Abstract available
    
    
    November 2016
71. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    PubMed     Text format     Abstract available
    
    
    October 2016
72. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    PubMed     Text format     Abstract available
    
    
    
73. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    PubMed     Text format    
    
    
    
74. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    PubMed     Text format     Abstract available
    
    
    
75. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    PubMed     Text format    
    
    
    
76. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    PubMed     Text format     Abstract available
    
    
    
77. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    PubMed     Text format     Abstract available
    
    
    
78. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    PubMed     Text format    
    
    
    
79. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available
    
    
    
80. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    PubMed     Text format    
    
    
    
81. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    PubMed     Text format    
    
    
    
82. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    PubMed     Text format     Abstract available
    
    
    September 2016
83. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    PubMed     Text format    
    
    
    August 2016
84. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    PubMed     Text format     Abstract available
    
    
    
85. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    PubMed     Text format     Abstract available
    
    
    
86. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    PubMed     Text format    
    
    
    
87. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    PubMed     Text format    
    
    
    
88. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    PubMed     Text format     Abstract available
    
    
    
89. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    PubMed     Text format     Abstract available
    
    
    July 2016
90. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    PubMed     Text format    
    
    
    
91. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    PubMed     Text format    
    
    
    
92. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    PubMed     Text format    
    
    
    
93. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    
    
    
    
94. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    PubMed     Text format    
    
    
    
95. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    
    
    
    
96. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    PubMed     Text format    
    
    
    
97. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    PubMed     Text format    
    
    
    June 2016
98. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    PubMed     Text format     Abstract available
    
    
    
99. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    PubMed     Text format    
    
    
    
100. MATHEW ST, Pakala AV, Thadani U
     Invasive strategy in acute coronary syndrome.
     Lancet. 2016;387:2503-4.
     PubMed     Text format    
     
     
     
101. SHAH R
     Invasive strategy in acute coronary syndrome.
     Lancet. 2016;387:2503.
     PubMed     Text format    
     
     
     
102. TIMMIS A
     Invasive strategy in acute coronary syndrome.
     Lancet. 2016;387:2503.
     PubMed     Text format    
     
     
     
103. POVSIC TJ, Zeiher AM
     IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
     Lancet. 2016;387:2362-3.
     PubMed     Text format    
     
     
     
104. FUJITA T
     Measurement of cardiac troponin for exclusion of myocardial infarction.
     Lancet. 2016;387:2289.
     PubMed     Text format    
     
     
     
105. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
     Measurement of cardiac troponin for exclusion of myocardial infarction.
     Lancet. 2016;387:2289.
     PubMed     Text format    
     
     
     
106. SHAH AS, Anand A, Chapman AR, Newby DE, et al
     Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
     Lancet. 2016;387:2289-91.
     PubMed     Text format    
     
     
     
107. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
     Measurement of cardiac troponin for exclusion of myocardial infarction.
     Lancet. 2016;387:2288.
     PubMed     Text format    
     
     
     
108. MULLEN L, Chew PG, Frost F, Obafemi T, et al
     Measurement of cardiac troponin for exclusion of myocardial infarction.
     Lancet. 2016;387:2288-9.
     PubMed     Text format    
     
     
     
109. DALE A, Slade E, Heneghan C
     Outcomes reporting of the FAME trial.
     Lancet. 2016;387:2292.
     PubMed     Text format    
     
     
     May 2016
110. LAFONT A, Mennuni MG
     Effect on death of scaffold thrombosis versus stent thrombosis.
     Lancet. 2016;387:2198.
     PubMed     Text format    
     
     
     
111. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
     Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
     Lancet. 2016 May 24. pii: S0140-6736(16)00378.
     PubMed     Text format     Abstract available
     
     
     
112. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
     Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
     Lancet. 2016 May 20. pii: S0140-6736(16)30467.
     PubMed     Text format     Abstract available
     
     
     
113. SABATE M, Brugaletta S
     Outcomes in the EXAMINATION trial - Authors' reply.
     Lancet. 2016;387:1998.
     PubMed     Text format    
     
     
     
114. DRYSDALE H, Hartley P, Goldacre B
     Outcomes in the EXAMINATION trial.
     Lancet. 2016;387:1997-8.
     PubMed     Text format    
     
     
     
115. CASSESE S, Kastrati A
     Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
     Lancet. 2016;387:1904.
     PubMed     Text format    
     
     
     
116. SHAH R, Ramos-Bondy B, Mizeracki A
     Risk of stent thrombosis with bioresorbable vascular scaffolds.
     Lancet. 2016;387:1903.
     PubMed     Text format    
     
     
     April 2016
117. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
     Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
     Lancet. 2016;387:1817-1826.
     PubMed     Text format     Abstract available
     
     
     
118. VAN 'T HOF AW, Ottervanger JP
     Primary angioplasty for STEMI: hard to improve upon.
     Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: